Clinical Trials
33
7 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
4
12.1%
Completed
17
51.5%
Not yet recruiting
3
9.1%
Recruiting
8
24.2%
Terminated
1
3.0%
No approval data available
- The gout therapeutics pipeline has expanded significantly with over 20 companies developing 25+ novel drugs across various clinical stages, addressing critical unmet needs in gout management. - Recent clinical milestones include Atom Therapeutics' ABP-671 achieving its primary endpoint in Phase IIb/III trials and multiple FDA Fast Track designations for promising candidates. - Key pipeline therapies utilize diverse mechanisms of action including URAT1 inhibitors, xanthine oxidase inhibitors, and inflammasome inhibitors to target different aspects of gout pathophysiology. - The market is positioned for sustained growth driven by rising disease prevalence, increasing awareness, and strong demand for effective long-term management solutions.
- Global hyperuricemia pipeline comprises 12+ key companies developing 15+ treatment therapies across various clinical stages, according to DelveInsight's 2025 report. - Leading companies in hyperuricemia drug development include LG Chem, Shanton Pharma, InventisBio, Jiangsu HengRui Medicine, and Selecta Biosciences, with treatments spanning oral, intravenous, and subcutaneous administration routes. - A significant development occurred in December 2024 when Atom Therapeutics partnered with China Medical System Holdings to commercialize lingdolinurad (ABP-671), a novel URAT1 inhibitor for chronic gout and hyperuricemia in China.
- InventisBio's D-2570, an oral TYK2 inhibitor, demonstrated significant efficacy in treating moderate to severe plaque psoriasis in a Phase 2 trial. - The study showed that a high percentage of patients achieved PASI 75, PASI 90, and PASI 100 responses with D-2570 compared to placebo at week 12. - D-2570 exhibited a favorable safety profile, with most adverse events being mild to moderate and no new safety signals identified. - These results suggest D-2570 could offer a convenient and effective oral alternative to biologics for psoriasis treatment.
- A new report highlights over 30 drugs in the gout pipeline, showcasing potential advancements in treatment strategies and offering hope for patients with this debilitating condition. - LG Chem's Tigulixostat, a novel xanthine oxidase inhibitor, is in Phase III trials as a potential first-line treatment for gout, demonstrating efficacy in lowering serum uric acid levels. - Shanton Pharma's SAP-001, a urate transporter inhibitor, is in Phase II development targeting refractory and tophaceous gout, addressing the needs of patients unresponsive to standard therapies. - InventisBio's D-0120, a selective URAT1 inhibitor, shows promise in Phase II trials with a potentially more potent uric acid-lowering effect and improved safety profile compared to existing treatments.
